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Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative disorders, related by 
signs of deteriorating motor and cognitive functions, and short survival. The cause is unknown and no effective treatment 
currently exists. For ALS, there is only a drug Riluzole and a promising substance arimoclomol. The overlap between 
ALS and FTD occurs at clinical, genetic, and pathological levels. The majority of ALS cases are sporadic (SALS) and a 
subset of patients has an inherited form of the disease, familial ALS (FALS), with a common SOD1 mutation, also present 
in SALS. A few of the mutant genes identified in FALS have also been found in SALS. Recently, hexanucleotide repeat 
expansions in C9ORF72 gene were found to comprise the largest fraction of ALS- and FTD-causing mutations known 
to date. TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene, has been identified as the pathological 
protein of FALS, SALS and, less frequently, FTD. The less frequent TDP-43 pathology in other forms of familial FTD 
has been linked to a range of mutations in GRN, FUS/TLS, rarely VCP, and other genes. TDP-43 and FUS/TLS have 
striking structural and functional similarities, most likely implicating altered RNA processing as a major event in ALS 
pathogenesis. The clinical overlap of the symptoms of FTD and ALS is complemented by overlapping neuropathology, 
with intracellular inclusions composed of microtubule-associated protein tau, TDP-43 and less frequently FUS, or unknown 
ubiquitinated proteins. Furthermore, new therapeutic approaches continue to emerge, by targeting SOD1, TDP-43 or 
GRN proteins. This review addresses new advances that are being made in our understanding of the molecular mechanisms 
of both diseases, which may eventually translate into new treatment options.
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Amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) are related neurodegenerative disorders, 
which are characterised by decline in motor and cognitive 
functions, and short survival. ALS is clinically characterised 
by signs of upper and lower motor neuron degeneration and 
its progressive spread of signs within a region or to other 
regions in a time frame, as defined by the revised El Escorial 
criteria (1). Both diseases have fatal outcome within a few 
years’ time (1). The cause is unknown and no effective 
treatment currently exists. There is a drug Riluzole, which 
slightly prolongs survival in patients with ALS (2), and a 
Phase II/III randomised, placebo-controlled trials of 
arimoclomol (BRX-345) in familial ALS with SOD-1 
mutation (NCT00706147; www.clinicaltrials.gov). The 
substance arimoclomol may reduce the levels of protein 
aggregates in motor nerves, a possible cause of ALS, by 
boosting expression of chaperons Hsp 70 and Hsp 90 which 
help newly synthesised proteins properly fold (3). 
In FTD, which usually clinically presents either 
behavioural abnormalities or language dysfunction, a 
considerable number of patients also develop muscle 
weakness and wasting that is typical for ALS (4, 5) or, vice 
versa, ALS patients develop impaired executive dysfunction 
and memory decline (6, 7). The presence of frontotemporal 
impairment in ALS predicts a shorter survival time (8) and 
behavioural and functional impairment may decline 
independently of motor function (9, 10).
The incidence of the ALS disease in Europe is 2.16 per 
100,000 (11), while for FTD the incidence is 3.5 per 100,000 
(12). Here we present a current understanding of molecular 
causes of ALS and FTD, in order to understand better 
pathogenetic mechanisms of both diseases as new design 
for clinical trials emerges in patients with ALS and FTD.  
Genetics
A growing number of ALS-causing genes have been 
identified recently. These are now under investigation as 
this could shed some light on the aetiology of the disease. 
In general, four major ALS-associated genes are superoxide 
dismutase 1 (SOD1), TAR DNA-binding protein (TARDBP), 
fusion in malignant liposarcoma (FUS), and the most 
common chromosome 9 open reading frame 72 (C9orf72). 
Mutations in the tubulin TUBA4A gene have also been 
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identified recently to be associated with ALS but also with 
FTD or mild cognitive impairment (13). 
In 2011, the discovery of the hexanucleotide repeat 
expansion in C9orf72 gene, as the most frequent genetic 
cause of ALS and FTD (14, 15), was a breakthrough: it was 
the first pathogenic mechanism identified to be a genetic 
link between familial FTD and dominant ALS. In particular, 
an expanded G4C2 repeat in C9orf72, the most common 
known genetic cause of both diseases, is pathogenic at 
greater than 30 repeats (16), with most patients having 
expansions >500 repeats, which is associated with C9ALS/
FTD. The characteristic pathological findings in both ALS 
and FTD are of dipeptide repeat (DPR) proteins. Possible 
molecular mechanisms of neurodegeneration include loss 
or gain of the C9orf72 protein function (10, 17). Loss of 
protein function reflects reduced levels of C9orf72 in 
patients’ brain and functional work revealing a role of 
C9orf72 protein in endocyclic and autophagic pathways 
(17). On contrary, the gain of function is supported by the 
presence of both repeat RNA and protein aggregates in 
patients’ brain. Repeat RNA aggregates, or RNA foci, have 
been shown to sequester proteins involved in RNA splicing, 
editing, nuclear export, and nuclear function. An alternative-
RNA-mediated mechanism to RNA binding protein is 
associated with non-TGA (RAN) translation that produces 
aberrant peptides or dipeptide polymers that form inclusions 
in patient tissue (18). In combating gain-of-function 
toxicity, oligonucleotides targeting C9orf72 showed success 
(19). 
Other three major ALS-associated genes, SOD1, located 
on chromosome 21, which encodes the Cu/Zn superoxide 
dismutase-1(20), TARDBP, and fusion in malignant 
liposarcoma/translocated in liposarcoma (FUS/TLS) have 
been identified with a growing number of ALS-causing 
genes. These genes are now under investigation as providing 
promise for increased understanding of further aetiology 
of the disease (21). Other genes, such as, angiogenin (ANG), 
the vesicle-associated membrane protein-associated protein 
B (VAPB), senataxin (SETX), and dynactin gene have been 
also identified in ALS patients. Mutations in the FUS/TLS 
gene, located on chromosome 16, have been identified as 
a causal gene for ~4 % of FALS (~0.4 % of all ALS) (22, 
23) and FTLD (24). As with TDP-43, FUS is a predominantly 
nuclear protein that is expressed at low levels in the 
cytoplasm (25). Although the phenotype associated with 
FUS mutation is variable, most patients predominantly 
demonstrate loss of lower motor neurons and short disease 
survival. Mutations in the SOD1 gene, located on 
chromosome 21 have been discovered in 1993 (20). Since 
than more than 120 different SOD1 mutations have been 
claimed responsible for 20 % of FALS cases (21). In 2008, 
Gitcho and colleagues (26) and  Sreedharan and colleagues 
(27) independently reported pathogenic mutations in the 
TARDBP gene located on chromosome 1 encoding TAR 
DNA-binding protein 43 (TDP-43), which cause several 
neurodegenerative diseases such as FALS, sporadic ALS, 
and FTLD. Their findings support a direct role of TARDBP 
mutations in neurodegeneration. TDP-43 is a 414-amino 
acid ubiquitously expressed nuclear protein, which contains 
two highly conserved RNA-recognition motifs (RRM1 and 
RRM2), a nuclear localisation signal at the N-terminus, and 
a glycin-rich region mediating protein-protein interactions 
at the C-terminus (25). Pathological C-terminal TDP-43 
fragments of 25 kDa are ubiquitinated, hyperphosphorylated 
and accumulated as cellular inclusions in neurons and glial 
cells (28). To define the link between mutations in TDP-43 
and the spectrum of relevant diseases, the TDP-43 mutant 
transgenic mice models with clinical features of ALS and 
FTD have been developed, however, with controversial 
results (29, 30). Although it is impossible to model 
accurately a clinical feature of human neurodegenerative 
diseases in mice, mouse models are able to recapitulate the 
key histopathological and biochemical features of both ALS 
and FTD, however not being very successful (31). The 
identification of SOD-1 mutations in FALS and MAPT 
mutations in FTDP-17 (20) induced the generation of 
TARDBP mutations in a variety of transgenic mouse models 
of either wild-type or mutant TDP-43 (32). However, none 
of these models is perfect. Mutations in GRN also result in 
TDP-43 neuropathology in humans, but knockout mice 
show little pathologically phosphorylated TDP-43 (33), 
thus not being able to elucidate the way GRN mutations 
leads to TDP-43 pathology in humans. Recently, the first 
(34) repeat-expansion mouse model and knockout mice was 
reported (35), but without a phenotypic description. The 
high prevalence of C9orf72 mutations in familial FTD-ALS 
suggests that accurate mouse models of this mutation are 
likely to contribute to drug development process. 
Neuropathology of ALS and FTLD
The clinical overlap of symptoms of ALS and FTD is 
complemented by overlapping neuropathology, such as the 
deposition of TDP-43 and FUS in patients with both 
diseases. 
The neuropathology of ALS is characterised by the 
abnormal accumulation of insoluble proteins in the 
cytoplasm of degenerating motor neurons (28, 36). Until 
recently, the specific biochemical composition of these 
neuronal cytoplasmic inclusions (NCIs) was rather 
unknown, except that the abnormal protein was ubiquitinated. 
These ubiquitin-immunoreactive (ub-ir) NCIs are most 
common in lower motor neurons and most often appear as 
either filamentous skeins or compact round bodies (36). 
ALS is accompanied by a wide range of neuropathological 
features in which both cortical (upper motor neuron) and 
either brainstem motor neurons or anterior horn cells (lower 
motor neuron) are involved with the signature lesion: 
abnormal accumulation of aggregated proteins in cytoplasm 
of degenerating motor neurons (37). Until recently, limited 
knowledge about the specific biochemical composition of 
these neuronal cytoplasmic inclusions existed, except that 
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biochemistry, and neuropathology of ALS and FTLD. The 
hexanucleotide C9orf72 expansion is the most common 
genetic cause of ALS and FTD, also associated with familial 
FTD with TDP-43 inclusions. Recently identified C9orf72, 
TARDBP, and FUS/TLS mutations define a novel class of 
neurodegenerative diseases called TDP-43-, FUS-
proteinopathies. The most frequent C9orf72 hexanucleotide 
repeat expansions, in which misfolded proteins are novel 
targets for the development of new diagnostic tests and 
therapeutics in this spectrum of diseases. Molecular 
mechanisms that underlie C9orf72-associated ALS and FTD 
neurodegeneration include loss- or gain of function of the 
C9orf72 protein. Together with gene (and stem cell) 
therapies the new discoveries are giving rise to an efficient 
ALS treatment. 
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Molekularna osnova ALS-a i FTD-a: implikacije za translacijska istraživanja
Amiotrofična lateralna skleroza (ALS) i frontotemporalna demencija (FTD) neurodegenerativni su poremećaji koji su 
povezani znakovima pogoršanja motoričkih i kognitivnih funkcija i kratkim vremenom preživljavanja. Uzrok je nepoznat 
i trenutačno ne postoji učinkovita terapija, tek lijek Riluzol i obećavajuća nova tvar arimoclomol za liječenje ALS-a. 
Preklapanje između ALS-a i FTD-a odvija se na kliničkoj, genetičkoj i patološkoj razini. Većina slučajeva ALS-a je 
sporadična (SALS), a podskupina bolesnika ima naslijeđeni oblik bolesti, obiteljski ALS (FALS), sa zajedničkom mutacijom 
SOD1, koja je prisutna i kod SALS-a. Nekoliko mutiranih gena koji su utvrđeni u FALS-u, pronađeni su i u SALS-u. 
Nedavno je utvrđeno da ponavljajući sljedovi heksanukleotida u genu C9orf72 sadrže najveću frakciju mutacija koje 
uzrokuju ALS i FTD, koja je poznata do danas. TAR DNA-povezujući protein 43 (TDP-43), koji kodira gen TARDBP, 
identificiran je kao patološki protein FALS-a, SALS-a i rjeđe FTD-a. Rjeđa TDP-43 patologija u drugim oblicima 
obiteljskoga FTD-a vezana je uz niz mutacija u GRN-u, FUS/TLS-u, rijetko VCP-u i drugim genima. TDP-43 i FUS/
TLS imaju velike strukturne i funkcionalne sličnosti, koje najvjerojatnije impliciraju izmijenjeno procesiranje RNA kao 
glavni događaj u patogenezi ALS-a. Kliničko preklapanje simptoma FTD-a i ALS-a nadopunjuje se preklapajućom 
neuropatologijom, s unutarstaničnim inkluzijama koje se sastoje od proteina tau povezanog s mikrotubulima, TDP-43 i 
rjeđe FUS-a ili nepoznatih ubikvitiniranih proteina. Nadalje, pojavljuju se novi terapijski pristupi koji ciljaju na SOD1, 
TDP-43 ili GRN proteine. Ovaj pregledni rad daje uvid u nova saznanja o molekularnim mehanizmima obiju bolesti koja 
bi se potencijalno mogla pretvoriti u nove mogućnosti liječenja. 
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